Business Context and Reporting Period
On June 15, 2023, Coherus BioSciences, Inc. (the "Company") filed a Form 8-K to report the entry into a definitive Agreement and Plan of Merger with Surface Oncology, Inc. ("Surface"). The transaction involves a two-step merger where Surface will become a wholly-owned subsidiary of Coherus. The filing date is June 15, 2023, with the public announcement made on June 16, 2023.
Key Financial Metrics and Transaction Structure
This filing details the terms of a proposed acquisition rather than reporting standard periodic financial results (e.g., revenue, net income, or cash flow) for a specific fiscal period. Key financial terms of the transaction include:
- Upfront Consideration: Surface shareholders will receive Coherus common stock based on an exchange ratio. The total value is calculated as $40,000,000 plus Surface's net cash at closing, divided by a fixed Coherus stock price of $5.2831, and then divided by the total fully-diluted Surface shares outstanding.
- Contingent Value Rights (CVRs): Each Surface share receives one CVR. These rights entitle holders to future payments based on specific milestones and royalties over a 10-year term.
- CVR Payment Sources:
- 70% of milestone and royalty payments from GlaxoSmithKline and Novartis agreements.
- 25% of net upfront payments for Surface's SRF114 candidate outside the U.S.
- 50% of net upfront payments for Surface's SRF388 candidate outside the U.S.
- Termination Fee: Surface is required to pay Coherus approximately $2,000,000 (less up to $500,000 in previously paid transaction expenses) if the agreement is terminated due to a superior proposal or a change in recommendation by Surface's board.
- Closing Condition: Surface must have net cash of no less than $19,600,000 as of the determination date.
Material Changes and Equity Treatment
The filing outlines significant changes to the capital structure of Surface and the treatment of its equity awards upon closing:
- Common Stock: Converted into Coherus stock and CVRs.
- In-the-Money Options: Cancelled and converted into Coherus stock (based on intrinsic value) and CVRs.
- Underwater Options:
- For continuing employees: Assumed by Coherus and converted to options for Coherus stock with adjusted share counts and exercise prices.
- For non-continuing employees: Cancelled with no consideration.
- RSUs: Automatically converted into the right to receive the Merger Consideration (Coherus stock and CVRs).
Guidance, Risks, and Contingencies
The filing contains extensive forward-looking statements and risk disclosures regarding the proposed transaction:
- Conditions to Closing: The merger is subject to Surface stockholder approval, effectiveness of a Form S-4 registration statement, Nasdaq listing approval, and the absence of material adverse effects.
- Termination Rights: Either party may terminate if the merger is not completed within six months of signing, or if certain representations are breached. Surface may terminate to accept a superior proposal.
- Key Risks:
- Failure to obtain stockholder or regulatory approvals.
- Uncertainty regarding the realization of anticipated benefits or synergies.
- Risk that CVR holders may not receive payments if milestones are not met.
- Potential dilution to Coherus shareholders from the issuance of new shares.
- Disruption to business operations and employee retention.
- Management Commentary: The filing emphasizes that the transaction is intended to expand Coherus's I-O franchise and leverage Surface's pipeline, but explicitly states that no assurance can be given that the transaction will be consummated.
Investor Verification Checklist
- Verify the final net cash position of Surface at closing to confirm it meets the $19.6 million threshold.
- Review the upcoming Form S-4 Registration Statement for the definitive proxy statement and prospectus.
- Monitor the status of Surface stockholder approval for the Merger Agreement.
- Assess the specific terms of the CVR Agreement (Exhibit A to the Merger Agreement) regarding payment calculations and deductions.
- Track the Nasdaq listing approval for the shares of Coherus common stock to be issued.
- Review Surface's and Coherus's recent 10-K and 10-Q filings for updated financial conditions and risk factors.